TGF-β pathway as a potential target in neurodegeneration and Alzheimer's

Current Alzheimer Research

Volumn 3, Issue 3, 2006, Pages 191-195

  Wyss Coray, Tony ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

AGING; ALZHEIMER DISEASE; BRAIN BLOOD VESSEL; CELL DAMAGE; CELL TYPE; CEREBROSPINAL FLUID; CEREBROVASCULAR MALFORMATION; COGNITION; FOREBRAIN; HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; NERVE CELL; NERVE DEGENERATION; NERVE FUNCTION; NEUROPROTECTION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURONS; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33745603438     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506777632916     Document Type: Review

References (63)

1. Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In: 'Alzheimer Disease'. (Eds: Terry RD, Katzman R, Bick KL), Raven Press, New York, p 179-96 (1994).
2. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-81 (2001).
3. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 27: 1-39 (1998).
4. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124 (2001).
5. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736 (2001).
6. Savaskan E, Muller-Spahn F, Olivieri G, Bruttel S, Otten U, Rosenberg C, et al . Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's disease. Eur Neurol 44: 172-80 (2000).
7. Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun 264: 648-51 (1999).
8. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al . BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58: 729-39 (1999).
9. Mocali A, Cedrola S, Della Malva N, Bontempelli M, Mitidieri VA, Bavazzano A, et al. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39: 1555-61 (2004).
10. De Servi B, La Porta CA, Bontempelli M, Comolli R. Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp Gerontol 37: 813-21 (2002).
11. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26: 115-23 (2005).
12. Hefti F. Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 37: 239-67 (1997).
13. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 97: 6826-31 (2000).
14. Massagué J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309 (2000).
15. Dennler S, Goumans M-J, Dijke Pt. Transforming growth factor β signal transduction. J Leukoc Biol 71: 731-40 (2002).
16. Lutz M, Knaus P. Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal 14: 977-88 (2002).
17. Letterio JJ. Murine models define the role of TGF-β as a master regulator of immune cell function. Cytokine Growth Factor Rev 11: 81-7 (2000).
18. Weinstein M, Yang X, Deng C-X. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 11: 49-58 (2000).
19. Roberts AB, Sporn MB. Transforming growth factor-β. In: 'The Molecular and Cellular Biology of Wound Repair, Second Edition'. (Ed: Clark RAF), Plenum Press, New York, p 275-308 (1996.
20. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-β: Structural features and mechanisms of activation. Kidney Int 51: 1376-82 (1997).
21. Khalil N. TGF-b: From latent to active. Microb Infect 1: 1255-63 (1999).
22. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-b type III receptor. Cell 67: 797-805 (1991).
23. López-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell 67: 785-95 (1991).
24. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95: 779-91 (1998).
25. Itoh S, Itoh F, Goumans M-J, ten Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem 267: 6954-67 (2000).
26. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 9: 87-115 (1989).
27. Dennler S, itoh S, Vivien D, Dijke PT, Huet S, Gauthier J-M. Direct binding of smad3 and smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitortype 1 gene. EMBO J 17: 3090-100 (1998).
28. Flanders KC, Ren RF, Lippa CF. Transforming growth factor-βs in neurodegenerative disease. Prog Neurobiol 54: 71-85 (1998).
29. Buckwalter M, Wyss-Coray T. Modelling neuroinflammatory phenotypes in vivo. J Neuroinflammation 1: 10 (2004).
30. Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM. TGF-β1 is an organizer of responses to neurodegeneration. J Cell Biochem 53: 314-22 (1993).
31. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700 (2003).
32. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000: 1153-60 (2000).
33. Grammas P, Ovase R. Cerebrovascular transforming growth factor-β contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 160: 1583-7 (2002).
34. Peress NS, Perillo E. Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 54: 802-11 (1995).
35. van der Wal EA, Gómez-Pinilla F, Cotman CW. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport 4: 69-72 (1993).
36. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23: 237-43 (2002).
37. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease. Nature 389: 603-6 (1997).
38. Wyss-Coray T, Lin C, Yan F, Yu G, Rohde M, McConlogue L, et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat Med 7: 614-8 (2001).
39. Tian J, Shi J, Bailey K, Mann DM. Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease. Neurosci Lett 352: 137-40 (2003).
40. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-b in Alzheimer's disease. Neurology 45: 1561-9 (1995).
41. Lippa CF, Flanders KC, Kim ES, Croul S. TGF-beta receptors-I and -II immunoexpression in Alzheimer's disease: a comparison with aging and progressive supranuclear palsy. Neurobiol Aging 19: 527-33 (1998).
42. Chao CC, Hu S, Frey WH, Ala TA, Tourtellotte WW, Peterson PK. Transforming growth factor β in Alzheimer's disease. Clin Diag Lab Immunol 1: 109-10 (1994).
43. Zetterberg H, Andreasen N, Blennow K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett 367: 194-6 (2004).
44. Wyss-Coray T, Lin C, Sanan D, Mucke L, Masliah E. Chronic overproduction of TGF-β1 in astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 156: 139-50 (2000).
45. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahue PK, et al . Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogensis. Proc Natl Acad Sci USA 97: 2626-31 (2000).
46. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 21: 1743-53 (2002).
47. Unsicker K, Krieglstein K. TGF-betas and their roles in the regulation of neuron survival. Adv Exp Med Biol 513: 353-74 (2002).
48. Gross CE, Bednar MM, Howard DB, Sporn MB. Transforming growth factor-β1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 24: 558-62 (1993).
49. Henrich-Noack P, Prehn JHM, Krieglstein J. TGF-β1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 27: 1609-15 (1996).
50. Pang L, Ye W, Che X-M, Roessler BJ, Betz AL, Yang G-Y. Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-β1 expression. Stroke 32: 544-52 (2001).
51. Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGF-beta1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40: 1133-45 (2003).
52. Ueberham U, Ueberham E, Bruckner MK, Seeger G, Gartner U, Gruschka H, Gebhardt R, Arendt T. Inducible neuronal expression of transgenic TGF-beta1 in vivo: dissection of short-term and long-term effects. Eur J Neurosci 22: 50-64 (2005).
53. Boche D, Cunningham C, Gauldie J, Perry VH. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab 23: 1174-82 (2003).
54. Zhu Y, Yang G-Y, Ahlemeyer B, Pang L, Che X-M, Culmsee C, et al. Transforming growth factor-β1 increases bad phosphorylation and protects neurons against damage. J Neurosci 22: 3898-909 (2002).
55. Prehn JH, Bindokas VP, Marcuccilli CJ, Krajewski S, Reed JC, Miller RJ. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci U S A 91: 12599-603 (1994).
56. Unsicker K, Krieglstein K. Co-activation of TGF-β and cytokine signaling pathways are required for neurotropic functions. Cytokine Growth Factor Rev 11: 97-102 (2000).
57. Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, Rockenstein EM, Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am J Pathol 147: 53-67 (1995).
58. Luckenbill-Edds L. Laminin and the mechanism of neuronal outgrowth. Brain Res Rev 23: 1-27 (1997).
59. Venstrom KA, Reichardt LF. Extracellular matrix. 2: Role of extracellular matrix molecules and their receptors in the nervous system. Faseb J 7: 996-1003 (1993).
60. Gaertner RF, Wyss-Coray T, Von Euw D, Lesne S, Vivien D, Lacombe P. Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities. Neurobiol Dis 19: 38-46 (2005).
61. Lesne S, Docagne F, Gabriel C, Liot G, Lahiri DK, Buee L, et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 278: 18408-18 (2003).
62. Monning U, Sandbrink R, Banati RB, Masters CL, Beyreuther K. Transforming growth factor beta mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Lett 342: 267-72 (1994).
63. Burton T, Liang B, Dibrov A, Amara F. Transforming growth factor-beta-induced transcription of the Alzheimer beta-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads. Biochem Biophys Res Commun 295: 713-23 (2002).